Intellia Therapeutics
Intellia seeks an Associate Scientist in Lipid Nanoparticle (LNP) Discovery to lead production, scale-up, and characterization of next-generation lipid-based delivery systems for nucleic acid therapeutics. The role involves designing and optimizing formulations, screening novel lipids, and interpreting data to advance their pipeline to preclinical stages. Collaboration across internal groups and external partners is essential for supplying high-quality results for in vitro and in vivo studies.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2014
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
1 week ago
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA)
3 days ago
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Intellia Therapeutics.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
2 weeks ago
Associate Scientist/Scientist I, LNP Formulations
Flagship Pioneering, Inc.
Contract SRA / Scientist, Lipid Nanoparticle (LNP) Discovery
Addition Therapeutics
Scientist
Sail Biomedicines
Senior Scientist, Delivery (Lipid/Polymer) Chemist
AstraZeneca
Senior Research Associate, LNP Production
Flagship Pioneering, Inc.
Scientist, Formulation Discovery
Eli Lilly and Company